series-a
Stage
1
Investors
About
DeuterOncology is developing deuterated MET kinase inhibitors, primarily DO-2 and its active metabolite DO-5, targeting MET exon 14 skipping mutations and MET amplification in non-small cell lung cancer (NSCLC) and other EGFR-driven cancers.
Explore DeuterOncology's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.